Sandoz is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 22,000 people of more than 100 nationalities work together to bring Sandoz medicines to 500 million patients worldwide, generating substantial global healthcare savings. Its leading portfolio of more than 1500 products addresses diseases from the common cold to cancer. In 2022, Sandoz achieved sales of USD 9.1 billion and core EBITDA of USD 1.9 billion.